Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
Main Authors: | Sylvie Chevret, Lila Bouadma, Claire Dupuis, Charles Burdet, Jean‑Francois Timsit, the COVIDICUS RCT group |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2023-09-01
|
Series: | Annals of Intensive Care |
Online Access: | https://doi.org/10.1186/s13613-023-01194-x |
Similar Items
-
Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
by: Sylvie Chevret, et al.
Published: (2023-08-01) -
Challenges of using external data in clinical trials- an illustration in patients with COVID-19
by: Sylvie Chevret, et al.
Published: (2022-12-01) -
Bayesian Sequential Design for Identifying and Ranking Effective Patient Subgroups in Precision Medicine in the Case of Counting Outcome Data with Inflated Zeros
by: Valentin Vinnat, et al.
Published: (2023-10-01) -
Which Reanalysis Dataset Should We Use for Renewable Energy Analysis in Ireland?
by: Eadaoin Doddy Clarke, et al.
Published: (2021-05-01) -
Influenza immunization policies: Which could be the main reasons for differences among countries?
by: Nicola Principi, et al.
Published: (2018-03-01)